| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00547066 Details | 2021-08-16 Interventional | 1/2 | 48 | Veltuzumab Purpura Purpura, Thromb… Purpura, Thromb… Autoimmune Thro… Purpura, Thromb… | - - | |||
| NCT04347980 Details | 2021-08-12 Interventional | 3 | 5 | Dexamethasone Hydroxychloroqu… Acute Lung Inju… COVID-19 Respiratory Dis… Respiratory Dis… Syndrome Respiratory Dis… | ANSM RECOMMANDATION - | |||
| NCT04342897 Details | 2021-08-12 Interventional | 2 | 95 | Zansecimab COVID-19 Pneumonia | Trial terminated for futility. The study was terminated for futility reason. | |||
| NCT03933761 Details | 2021-08-10 Interventional | 2 | 0 | Pamiparib Carcinoma, Ovar… Carcinosarcoma Mixed Tumor, Mu… Ovarian Neoplas… Ovarian Cancer | No eligible patient identified after 18 evaluable patients underwent pre-screening over a 2
year period. - | |||
| NCT02041299 Details | 2021-08-10 Interventional | 4 | 230 | Deferiprone Deferoxamine Anemia Anemia, Sickle … Iron Overload Other Anemias Sickle Cell Dis… | Difficulties with additional recruitment as pool of potential patients was exhausted, and
sufficient information for determination of study outcome measure was already obtained The trial was terminated early as the pool of potential participants was exhausted and it was determined that the number of patients already randomized would be sufficient to assess the primary endpoint. | |||
| NCT02732015 Details | 2021-08-09 Interventional | 2 | 37 | Aprepitant BB 1101 Daunorubicin Dexamethasone Dexamethasone a… Doxorubicin Fosaprepitant Ifosfamide Isophosphamide … Liposomal doxor… Mesna Ondansetron Rolapitant Vincristine Sarcoma Vomiting Locally Advance… | Terminated per PI's request - | |||
| NCT01988090 Details | 2021-08-09 Interventional | 2 | 93 | Cholecalciferol Ergocalciferols Vitamin D Vitamins Breast Neoplasm… Breast Cancer | An interim analysis demonstrated no benefit of high dose vitamin D when compared to standard
dose vitamin D in the reduction or prevention of arthralgia - | |||
| NCT03521479 Details | 2021-08-06 Interventional | 2 | 40 | Squaric acid di… Herpes Labialis Herpes Simplex HSV | Study drug out of specification - | |||
| NCT02127151 2013-003469-32 Details | 2021-08-06 Interventional | 2 | 0 | Talazoparib Endometrial Neo… Endometrial Can… | Withdrawal of Industry support for the study - | |||
| NCT04032171 2018-004700-19 Details | 2021-08-05 Interventional | 3 | 1 | Interferon beta… Multiple Sclero… Multiple Sclero… Sclerosis Relapsing-remit… | Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086),
it was determined that a change in active comparator warranted in phase 3 RMS comprised of
trial MS200527-0074. Consequently, this trial terminated early. Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0074. Consequently, this trial terminated early, therefore, it was decided as per Statistical Analysis Plan not to report the efficacy data for this study. | |||
| NCT04032158 2018-004701-11 Details | 2021-08-05 Interventional | 3 | 3 | Interferon beta… Multiple Sclero… Multiple Sclero… Sclerosis Relapsing-remit… | Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086),
it was determined that a change in active comparator warranted in phase 3 RMS comprised of
trial MS200527-0073. Consequently, this trial terminated early. Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0073. Consequently, this trial terminated early, therefore, it was decided as per Statistical Analysis Plan not to report the efficacy data for this study. | |||
| NCT02985021 Details | 2021-08-05 Interventional | 2 | 2 | Carboplatin Docetaxel Carcinoma DNA Repair-Defi… Prostatic Neopl… Hormone-Resista… Metastatic Pros… Recurrent Prost… Stage IV Prosta… | Competing studies - | |||
| NCT03656692 Details | 2021-08-03 Interventional | 4 | 5 | Adrenocorticotr… Panuveitis Pars Planitis Uveitis Uveitis, Interm… Uveitis, Poster… | Logistical challenges; no safety concerns - | |||
| NCT02521870 Details | 2021-08-03 Interventional | 1/2 | 241 | Pembrolizumab Carcinoma Carcinoma, Squa… Head and Neck N… Melanoma Squamous Cell C… Head Neck Cance… Metastatic Mela… | A strategic restructuring including the planned conclusion of clinical oncology development
programs and no further sponsoring of the development of SD-101. The sponsor terminated the trial early due to strategic restructuring, including the planned conclusion of clinical oncology development programs and no further sponsoring of the development of SD-101. | |||
| NCT01968356 Details | 2021-08-03 Interventional | 3 | 171 | Chlorhexidine Chlorhexidine g… Ethanol Skin Flora Bact… | Study discontinued due to data quality issues. - | |||
| NCT00999518 2009-014597-17 Details | 2021-08-03 Interventional | 2 | 205 | Tanezumab Cystitis Cystitis, Inter… | See termination reason in detailed description. The study was terminated due to lack of efficacy of all doses of tanezumab demonstrated during pre-planned interim analysis. | |||
| NCT04162028 Details | 2021-07-30 Interventional | 4 | 0 | Ketamine Pain | Investigators not interested any more in the study - | |||
| NCT03158116 Details | 2021-07-30 Interventional | 4 | 5 | Aztreonam Pseudomonas Inf… Tracheostomy In… | IRB application expired. The study has limitations with the primary one being it is a very small study. The intention was to have a larger study multi-center study. However, due to multi-site institutional research logistics and administrative bureaucracy, expanding the study was not possible. | |||
| NCT01946152 Details | 2021-07-30 Interventional | 1/2 | 21 | BB 1101 Dexamethasone Dexamethasone a… Ichthammol Lenograstim Pomalidomide Multiple Myelom… Neoplasms, Plas… Multiple Myelom… Recurrent Plasm… Refractory Plas… | Per PI at time of CR - | |||
| NCT01651936 2012-002181-12 Details | 2021-07-30 Interventional | 2 | 56 | Methotrexate Arthritis Arthritis, Rheu… Rheumatoid Arth… | - This study was terminated early (12 September 2013) based on preliminary analysis of data. The results of this study need to be interpreted with caution given the small sample size (56 participants) resulting from early termination of the study. |